International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“What were some of the most impactful highlights from WCLC25 on Monday?
In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu bring you the latest data with insights from:
- Dr. Tina Cascone on the NADIM ADJUVANT Phase III trial.
- Dr. Jacie Jiaqi Law on survival outcomes of VATS vs open lobectomy.
- Dr. Corinne Faivre-Finn and Dr. Shankar Siva on EA5181 (durvalumab after chemoradiation for unresectable NSCLC) and hypofractionation vs conventional fractionation in LS SCLC.
More Posts Featuring IASLC.